| Sheila Sponselee |
Sheila Sponselee currently works at ProQR Therapeutics NV, as Chief Operations & People Officer. |
| Jurriaan Dekkers |
Jurriaan Dekkers is the founder of Dr. Decorum. He is currently the Chief Financial Officer at ProQR Therapeutics NV since 2022. He is also a Member-Supervisory Board at Stichting Kinderpostzegels Nederland. Previously, he worked as the Chief Financial Officer & Director at Acerta Pharma BV and as the Chief Financial Officer at AstraZeneca BV. He graduated from Rotterdam University. |
| Daniel Anton de Boer |
Daniel Anton de Boer is the founder of ProQR Therapeutics NV, PC Basic B.V., and Running It. He held the position of Chief Executive Officer at each of these companies. Additionally, he is also the founder of Amylon Therapeutics BV. |
| Theresa Marie Heggie |
Theresa Marie Heggie is currently an Independent Director at BioCryst Pharmaceuticals, Inc. She is also a Co-Managing Director at Alnylam Germany GmbH and a Director at Alnylam UK Ltd. Additionally, she serves as a Member-Supervisory Board at ProQR Therapeutics NV. In her former positions, Ms. Heggie was the Chief Executive Officer at Shire Orphan Therapies GmbH from 2008 to 2009. She also held the position of Chief Executive Officer at Freeline Therapeutics Ltd. Furthermore, she served as the Chief Executive Officer & Director at Freeline Therapeutics Holdings Plc from 2020 to 2021. Ms. Heggie was an Independent Non-Executive Director at Swedish Orphan Biovitrum AB from 2016 to 2017. She also worked as the Vice President-Global Marketing at Baxter International, Inc. and as a Principal at Janssen Pharmaceuticals, Inc. Ms. Heggie held the position of Senior Vice President-Global Commercial Operations at Shire Plc from 2005 to 2008. She was the Chief Marketing & Strategy Officer at The British United Provident Association Ltd. from 2013 to 2016. Additionally, she served as the Senior Vice President, Head-EMEA & Canada Region at Alnylam Pharmaceuticals, Inc. from 2017 to 2020. Ms. Heggie was the Senior Vice President-Global Commercial Operations at Shire Human Genetic Therapies, Inc. from 2010 to 2013. She also worked as a Principal at Ohmeda Pharmaceuticals. Ms. Heggie completed her undergraduate degree at Cornell University. |
| Gerard J. Platenburg |
Gerard J. Platenburg is the founder of Prosensa Holding NV, which was founded in 2002. He held the title of Chief Executive & Development Officer from 2002 to 2009. He is also the founder of ProQR Therapeutics NV, which was founded in 2012. Currently, he holds the title of Chief Scientific Officer at ProQR Therapeutics NV. Mr. Platenburg's former job includes being the Chief Executive Officer at ISA Pharmaceuticals BV from 2009 to 2014. He also worked at Pharming NV as a Principal. Mr. Platenburg obtained his graduate degree from the University of Leiden in 1987. |
| René Beukema |
René Beukema is the founder of Impatients NV, which was founded in 2012. He is currently a Member at Vu Medical Center and the Chief Corporate Development Officer at ProQR Therapeutics NV since 2022. Previously, he held the position of Director at Fibriant BV from 2021 to 2024. He also served as the Corporate Secretary & General Counsel at Crucell NV from 2010 to 2012. Dr. Beukema was a Senior Legal Counsel at T.I.P. Europe Ltd. and GE Capital Europe Ltd. from 1994 to 1999. He was also the Corporate Secretary & General Counsel at Janssen Vaccines & Prevention BV. Additionally, he worked as a Partner at Aescap Venture Management BV from 2011 to 2013. Dr. Beukema started his career as a Legal Counsel at TNT Express Worldwide BV from 1991 to 1994. He later served as the General Counsel at ProQR Therapeutics NV from 2013 to 2018. Dr. Beukema holds a graduate degree from the University of Amsterdam and a doctorate degree from Radboud University Nijmegen. |
| Domenico Valerio |
Domenico Valerio is the founder of Galapagos Genomics NV (founded in 1999) and Crucell NV (founded in 2000). He is also the founder of Aescap Venture Management BV (founded in 2005) and ProQR Therapeutics NV (founded in 2012), where he holds the title of Chairman-Supervisory Board. Dr. Valerio is also the founder of Leyden Laboratories B.V. His current job(s) include being a Non-Executive Director at Biocartis SA since 2012, a Managing Director at Stichting Administratiekantoor. Endavit, a Professor at the University of Leiden since 1992, and a Member-Supervisory Board at Amylon Therapeutics BV since 2017. His former job(s) include being a Vice Chairman-Supervisory Board at Affectis Pharmaceuticals AG, a Director at Intrexon ActoBiotics NV and EOS SpA, and a Director at Vivendy Therapeutics Ltd. from 2013 to 2014. He also served as a Non-Executive Director at Biocartis Group NV. Dr. Valerio obtained a graduate degree from the University of Amsterdam in 1982 and a doctorate degree from the University of Leiden in 1986. |
